Company

uniQure N.V.

Headquarters: Amsterdam, Netherlands

Employees: 463

CEO: Mr. Matthew Craig Kapusta

NASDAQ: QURE -0.74%

Market Cap

$187.9 Million

USD as of July 1, 2024

Market Cap History

uniQure N.V. market capitalization over time

Evolution of uniQure N.V. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of uniQure N.V.

Detailed Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

uniQure N.V. has the following listings and related stock indices.


Stock: NASDAQ: QURE wb_incandescent

Stock: XETR: UQ1 wb_incandescent

Stock: FSX: UQ1 wb_incandescent

Details

Headquarters:

Paasheuvelweg 25a

Amsterdam, 1105 BP

Netherlands

Phone: 31 20 240 6000